At close: December 13 at 4:00:01 PM EST
After hours: December 13 at 5:25:13 PM EST
Key Executives
Amounts are as of December 31, 2020 and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in USD.
| Name | Title | Pay | Exercised | Year Born |
|---|---|---|---|---|
| Mr. John G. Cox M.B.A. | CEO, President & Director | -- | -- | 1963 |
| Dr. Romesh Subramanian Ph.D. | Co-Founder & Advisor | 565.17k | -- | 1965 |
| Mr. Richard William Scalzo M.B.A. | Senior VP and Head of Finance & Administration | -- | -- | 1986 |
| Mr. John Najim M.B.A. | Chief Technical Officer | -- | -- | -- |
| Dr. Oxana Beskrovnaya Ph.D. | Chief Scientific Officer | 631.08k | -- | 1961 |
| Ms. Amy Reilly | Senior VP and Head of Corporate Communications & Investor Relations | -- | -- | 1974 |
| Mr. Daniel Wilson | Senior VP & Head of Legal | -- | -- | 1972 |
| Ms. Lucia Celona | Chief Human Resource Officer | -- | -- | 1966 |
| Ms. Debra Feldman | Chief Regulatory Affairs Officer | -- | -- | 1971 |
| Dr. Ashish Dugar M.B.A., Ph.D. | Chief Medical Affairs Officer | -- | -- | -- |
Dyne Therapeutics, Inc.
- Sector:
- Healthcare
- Industry: Biotechnology
- Full Time Employees:
- 173
Description
Dyne Therapeutics, Inc., a clinical-stage muscle disease company, operates as a biotechnology company that focuses on advancing therapeutics for genetically driven muscle diseases in the United States. It is developing a portfolio of muscle disease therapeutics, including programs in myotonic dystrophy type 1; duchenne muscular dystrophy; and facioscapulohumeral dystrophy, as well as rare skeletal muscle, and cardiac and metabolic muscle diseases using its FORCE platform that delivers disease-modifying therapeutics. Dyne Therapeutics, Inc. was incorporated in 2017 and is headquartered in Waltham, Massachusetts.
Corporate Governance
Dyne Therapeutics, Inc.’s ISS Governance QualityScore as of December 1, 2024 is 8. The pillar scores are Audit: 8; Board: 8; Shareholder Rights: 8; Compensation: 8.
Corporate governance scores courtesy of Institutional Shareholder Services (ISS) Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while a 10 indicates higher governance risk.
Upcoming Events
March 3, 2025 at 1:30 PM UTC - March 7, 2025 at 1:30 PM UTC
Dyne Therapeutics, Inc. Earnings Date
Recent Events
Related Tickers
RNA Avidity Biosciences, Inc.
32.49
-3.76%
EWTX Edgewise Therapeutics, Inc.
27.62
-1.88%
CNTA Centessa Pharmaceuticals plc
16.57
-1.78%
VERA Vera Therapeutics, Inc.
44.05
-2.35%
APGE Apogee Therapeutics, Inc.
44.50
+0.41%
CGON CG Oncology, Inc.
28.76
-0.38%
KYMR Kymera Therapeutics, Inc.
42.13
-0.09%
BCAX Bicara Therapeutics Inc.
17.50
-3.02%
NUVL Nuvalent, Inc.
86.86
+0.05%
WVE Wave Life Sciences Ltd.
13.44
-2.96%